Somewhat Positive Press Coverage Somewhat Unlikely to Affect Akcea Therapeut (NASDAQ:AKCA) Share Price

Media stories about Akcea Therapeut (NASDAQ:AKCA) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Akcea Therapeut earned a news sentiment score of 0.19 on Accern’s scale. Accern also gave news headlines about the company an impact score of 46.510663091206 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

A number of research firms have recently weighed in on AKCA. BMO Capital Markets began coverage on shares of Akcea Therapeut in a research note on Tuesday, August 8th. They issued an “outperform” rating and a $25.00 price target on the stock. Stifel Nicolaus began coverage on shares of Akcea Therapeut in a research note on Tuesday, August 8th. They issued a “buy” rating and a $19.00 price target on the stock. Wells Fargo & Company began coverage on shares of Akcea Therapeut in a research note on Tuesday, August 8th. They issued an “outperform” rating and a $27.00 price target on the stock. Finally, Cowen and Company began coverage on shares of Akcea Therapeut in a research report on Tuesday, August 8th. They set an “outperform” rating on the stock.

Akcea Therapeut (AKCA) opened at 14.10 on Friday. Akcea Therapeut has a 52-week low of $8.10 and a 52-week high of $16.30. The firm’s 50-day moving average is $11.33 and its 200 day moving average is $11.33. The firm’s market capitalization is $905.19 million.

In other Akcea Therapeut news, major shareholder Ionis Pharmaceuticals Inc purchased 3,125,000 shares of the stock in a transaction on Wednesday, July 19th. The shares were purchased at an average cost of $8.00 per share, for a total transaction of $25,000,000.00. Following the purchase, the insider now owns 28,884,540 shares of the company’s stock, valued at $231,076,320. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

COPYRIGHT VIOLATION NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Akcea Therapeut (NASDAQ:AKCA) Share Price” was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.com-unik.info/2017/08/19/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-akcea-therapeut-nasdaqakca-share-price-updated.html.

About Akcea Therapeut

Akcea Therapeutics, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company’s drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc (Ionis).

What are top analysts saying about Akcea Therapeut? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Akcea Therapeut and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit